Definium says its LSD drug notched another Phase 3 win in anxiety disorder
Phase 3positiveDT120Positive
AI Analysis
Summary
Definium Therapeutics reported positive Phase 3 results for its oral LSD candidate DT120 in anxiety disorder, marking the company's third Phase 3 readout this year. The company is preparing for FDA submission.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 trial met primary endpoint in anxiety disorder
Importance:8/10
Sentiment:
0.80
Phase 3 dataLSDAnxiety disorderFDA submission planned
Read the original article
Published by Endpoints News on September 14, 2026 11:00 AM